ConsultantLive via MedWorm.com MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'ConsultantLive' source. Sat, 10 Oct 2009 19:30:04 +0100 Umbilical cord blood transplant alternative for older pts http://www.medworm.com/index.php?rid=1269683&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801586%26CID%3Drss While reduced-intensity conditioning allows hematopoietic stem cell transplant (HSCT) in older cancer patients who cannot tolerate standard conditioning regimens, only about one-third of such patients have an HLA-matched related donor available. For these patients, stem cells derived from unrelated umbilical cord blood (UCB) may provide a suitable and convenient alternative (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1269683 Sat, 01 Mar 2008 09:22:13 +0100 1269683 Study spells end for high-dose dex in first-line myeloma pts http://www.medworm.com/index.php?rid=1269682&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801585%26CID%3Drss In newly diagnosed multiple myeloma patients, lenalidomide (Revlimid) plus low-dose dexamethasone led to superior overall survival, compared with the standard regimen of lenalidomide plus high-dose dexamethasone (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1269682 Sat, 01 Mar 2008 09:22:13 +0100 1269682 Large adjuvant trial shows no benefit of adding a taxane http://www.medworm.com/index.php?rid=1268657&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801591%26CID%3Drss Sequential docetaxel (Taxotere)-based chemotherapy did not lead to better outcomes than standard anthracycline-based chemotherapy among women with resected breast cancer in the Taxotere as Adjuvant Chemotherapy Trial (TACT), the largest primary adjuvant trial of taxanes to date. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1268657 Fri, 29 Feb 2008 21:34:25 +0100 1268657 Inaccurate lab reports put breast cancer patients at risk http://www.medworm.com/index.php?rid=1268656&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801590%26CID%3Drss Studies show that thousands of women may be receiving the wrong breast cancer treatment because of faulty laboratory reports. More disturbing, this trend was identified years ago. A 2006 study led by Genentech found 14% to 16% of HER2 tests were false positive and 18% to 23% were false negative. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1268656 Fri, 29 Feb 2008 21:34:25 +0100 1268656 VTD induction boosts CRs in newly diagnosed myeloma http://www.medworm.com/index.php?rid=1268655&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801589%26CID%3Drss ;In patients with newly diagnosed multiple myeloma, the addition of bortezomib (Velcade) to thalidomide (Thalomid) and dexamethasone significantly increased response rates, compared with thalidomide plus dexamethasone alone, when used as induction therapy prior to autologous stem cell transplant (ASCT (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1268655 Fri, 29 Feb 2008 21:34:25 +0100 1268655 Stage set for further trials of rIL-2 in younger AML pts http://www.medworm.com/index.php?rid=1268654&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801588%26CID%3Drss Preliminary results suggest that immunotherapy with recombinant interleukin-2 (rIL-2) may prolong survival in younger patients with acute myeloid leukemia in first remission. However, the high rate of refusal or discontinuation of such therapy presents challenges for its acceptance (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1268654 Fri, 29 Feb 2008 21:34:25 +0100 1268654 Frontline alemtuzumab promising for high-risk CLL pts http://www.medworm.com/index.php?rid=1268653&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801587%26CID%3Drss A novel frontline regimen has shown efficacy in high-risk patients with chronic lymphocytic leukemia, with no significant increase in hematologic toxicity, compared with historical data on the standard regimen (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1268653 Fri, 29 Feb 2008 21:34:25 +0100 1268653 Good nilotinib responses in imatinib-resistant AP-CML http://www.medworm.com/index.php?rid=1265328&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801594%26CID%3Drss Among Ph+ chronic myelogenous leukemia patients in accelerated phase with imatinib (Gleevec) resistance or intolerance, treatment with nilotinib (Tasigna) rapidly produced significant responses and was generally well tolerated in an open-label pivotal phase II study (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1265328 Thu, 28 Feb 2008 21:30:42 +0100 1265328 Assay has high sensitivity for hard-to-detect SLN mets http://www.medworm.com/index.php?rid=1265327&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801593%26CID%3Drss A rapid molecular assay outperforms frozen sections when it comes to detecting breast cancer metastases in sentinel lymph nodes (SLNs), new data show. Moreover, the assay tends to perform better in cases where detection of metastases by frozen section is known to be difficult, such as cases of lobular carcinoma. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1265327 Thu, 28 Feb 2008 21:30:42 +0100 1265327 Sequential Rx effective, less toxic in metastatic breast ca http://www.medworm.com/index.php?rid=1265326&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801592%26CID%3Drss As first-line treatment for metastatic breast cancer in HER2-positive patients, trastuzumab (Herceptin) can be given as a single agent, followed by docetaxel (Taxotere) upon progression, without compromising time to recurrence and providing a better toxicity profile (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1265326 Thu, 28 Feb 2008 21:30:42 +0100 1265326 Kosan opens TIME-1 pivotal trial of tanespimycin in myeloma http://www.medworm.com/index.php?rid=1261851&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801603%26CID%3Drss Kosan Biosciences Incorporated has announced that the Tanespimycin in Myeloma Evaluation (TIME-1) pivotal phase III trial for its Hsp90 inhibitor tanespimycin as a potential treatment for multiple myeloma is open for enrollment (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1261851 Wed, 27 Feb 2008 21:45:07 +0100 1261851 M.D. Anderson and AstraZeneca form neuropathic pain alliance http://www.medworm.com/index.php?rid=1261850&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801602%26CID%3Drss M.D. Anderson Cancer Center and AstraZeneca will collaborate to help advance the understanding of neuropathic pain caused by cancer chemotherapy. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1261850 Wed, 27 Feb 2008 21:45:07 +0100 1261850 FDA reviewing sBLA for Pegintron for melanoma http://www.medworm.com/index.php?rid=1261849&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801601%26CID%3Drss Schering-Plough Corporation has announced that FDA has granted priority review to its supplemental Biologics License Application for Pegintron (pegylated interferon alfa-2b) as adjuvant therapy for patients with stage III melanoma. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1261849 Wed, 27 Feb 2008 21:45:07 +0100 1261849 FDA approves new adjuvant indication for Herceptin http://www.medworm.com/index.php?rid=1261848&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801600%26CID%3Drss The FDA has approved a new indication for Genentech's Herceptin (trastuzumab) as a single agent for the adjuvant treatment of HER2-overexpressing, node-negative (ER/PR-negative or with one high-risk feature) or node-positive breast cancer, following multimodality anthracycline-based therapy. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1261848 Wed, 27 Feb 2008 21:45:07 +0100 1261848 Virus linked to Merkel cell carcinoma http://www.medworm.com/index.php?rid=1261847&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801599%26CID%3Drss University of Pittsburgh Cancer Institute researchers have discovered a previously unknown virus strongly associated with Merkel cell carcinoma, a rare but aggressive skin cancer that typically affects elderly and immunosuppressed individuals (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1261847 Wed, 27 Feb 2008 21:45:07 +0100 1261847 Are HBV and HPV infection only the tip of the iceberg? http://www.medworm.com/index.php?rid=1261846&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801598%26CID%3Drss Modern medicine has made most infectious diseases of bacterial origin easily managed. However, research has shown that chronic infections caused by a handful of viruses, bacteria, and parasites play a significant role in the development of certain cancers. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1261846 Wed, 27 Feb 2008 21:45:07 +0100 1261846 Whole body staging can miss melanoma and lung mets http://www.medworm.com/index.php?rid=1261845&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801597%26CID%3Drss In a surprising discovery, reported at RSNA 2007, researchers from Germany have found that whole-body staging of patients with recently diagnosed malignant melanoma using either MRI or PET/CT could miss a substantial number of metastatic lesions (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1261845 Wed, 27 Feb 2008 21:45:07 +0100 1261845 Rituximab effective in first-line CLL http://www.medworm.com/index.php?rid=1261844&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801596%26CID%3Drss In a pivotal phase III study, rituximab (Rituxan) in combination with standard chemotherapy significantly increased time to progression in patients with previously untreated chronic lymphocytic leukemia (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1261844 Wed, 27 Feb 2008 21:45:07 +0100 1261844 Mutational status affects nilotinib responses in CP-CML http://www.medworm.com/index.php?rid=1261843&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801595%26CID%3Drss In a significant proportion of imatinib (Gleevec)-resistant chronic-phase chronic myelogenous leukemia patients with Bcr-Abl mutations, nilotinib (Tasigna) treatment results in hematologic, cytogenetic, and molecular responses (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1261843 Wed, 27 Feb 2008 21:45:07 +0100 1261843 ACCC views 2008 as a year of economic challenges http://www.medworm.com/index.php?rid=1253339&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801574%26CID%3Drss Since the passage of the Medicare Modernization Act of 2003, community cancer centers around the country have been struggling to balance the delivery of optimum care with an ever-tightening reimbursement climate. Cancer Care & Economics (CC&E) talked with the Association of Community Cancer Centers (ACCC) Manager of Provider Economics & Public Policy, Matthew Farber, MA, about the challenges of the upcoming year. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1253339 Mon, 25 Feb 2008 09:29:53 +0100 1253339 Making faster, better, more cost-effective clinical trials http://www.medworm.com/index.php?rid=1253338&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801573%26CID%3Drss Over the past few years, the number of new cancer drugs approved by FDA has been dwindling. Critics generally cite exorbitant costs, lack of accrual to trials, conflicts of interest, and government regulations as the primary reasons for the dearth of new molecular compounds. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1253338 Mon, 25 Feb 2008 09:29:53 +0100 1253338 New machine approved for adaptive RT http://www.medworm.com/index.php?rid=1253337&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801572%26CID%3Drss Siemens Medical Solutions announced it has received FDA 510(k) marketing clearance for its ARTISTE Solution, a linear accelerator engineered specifically for Adaptive Radiation Therapy (ART). (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1253337 Mon, 25 Feb 2008 09:29:53 +0100 1253337 Plerixafor boosts stem cell mobilization in myeloma pts http://www.medworm.com/index.php?rid=1253336&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801571%26CID%3Drss Patients with multiple myeloma are more likely to mobilize sufficient numbers of hematopoietic stem cells (HSCs) when plerixafor (AMD3100) is given with G-CSF (Neupogen) than with G-CSF alone. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1253336 Mon, 25 Feb 2008 09:29:53 +0100 1253336 For resectable liver mets: Preop chemotherapy or not? http://www.medworm.com/index.php?rid=1253335&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801570%26CID%3Drss When colorectal cancer metastasizes to the liver, hepatic resection can offer a survival benefit and even a "cure" in a fraction of patients. Five-year overall survival in some recent series approaches 60%. But the role of neoadjuvant chemotherapy in this group of patients has not been well established (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1253335 Mon, 25 Feb 2008 09:29:53 +0100 1253335 Study may answer critics' fears about preop breast MRI http://www.medworm.com/index.php?rid=1253334&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801569%26CID%3Drss Greater utilization of dynamic contrast-enhanced MRI at the University of California, San Diego, over a 6-year period helped improve surgery planning for tough breast cancer cases without hiking mastectomy rates (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1253334 Mon, 25 Feb 2008 09:29:53 +0100 1253334 Danish researchers claim possible 'cure' of MCL http://www.medworm.com/index.php?rid=1253333&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801568%26CID%3Drss Use of intensive immunochemotherapy plus purged stem-cell support can result in long-term survival in patients with mantle cell lymphoma, suggesting that MCL could be considered as curable. Christian Geisler, MD, PhD, of Rigshospitalet, Copenhagen, Denmark, presented this provocative idea, based on final results of the MCL2 study, at ASH 2007 (abstract LB1), speaking on behalf of the Nordic Lymphoma Group. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1253333 Mon, 25 Feb 2008 09:29:53 +0100 1253333 Diagnostic Dilemma: Dermatology http://www.medworm.com/index.php?rid=1253332&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801567%26CID%3Drss A 31-year-old man presented in May 2007 with generalized painful, ulcerated, and necrotic papules and plaques worsening for the last few months. He had been diagnosed with mycosis fungoides in October 2005. Treatments included topical corticosteroids and psoralen with ultraviolet A light therapy (PUVA), with the latter being discontinued because of the development of blisters. For the last 6 months, he had been treated with oral bexarotene (Targretin), with initial improvement of his skin lesions. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1253332 Mon, 25 Feb 2008 09:29:53 +0100 1253332 Study ends adjuvant controversy? http://www.medworm.com/index.php?rid=1253331&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801558%26CID%3Drss Overall survival after pancreatic resection can be markedly improved with adjuvant chemoradiation therapy, according to investigative groups who presented encouraging data on two different regimens at the 2008 Gastrointestinal Cancers Symposium. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1253331 Mon, 25 Feb 2008 09:29:53 +0100 1253331 Dasatinib effective in imatinib resistant/intolerant CML http://www.medworm.com/index.php?rid=1253330&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801609%26CID%3Drss Study results presented at ASH 2007 showed efficacy of the novel tyrosine kinase inhibitor dasatinib (Sprycel) in imatinib (Gleevec) resistant or intolerant chronic myelogenous leukemia patients in chronic, accelerated, and blast phase (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1253330 Mon, 25 Feb 2008 09:29:53 +0100 1253330 MRI shows second-hand smoke damage http://www.medworm.com/index.php?rid=1253329&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801608%26CID%3Drss A new MRI technique—inhaled hyperpolarized helium-3 diffusion MRI—shows lung damage in nonsmokers exposed to second-hand smoke (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1253329 Mon, 25 Feb 2008 09:29:53 +0100 1253329 Minimally invasive methods accurately stage lung cancer http://www.medworm.com/index.php?rid=1253328&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801607%26CID%3Drss Two minimally invasive staging methods used together may be an accurate substitute for mediastinoscopy for some lung cancer patients with suspected metastatic mediastinal lymph nodes (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1253328 Mon, 25 Feb 2008 09:29:53 +0100 1253328 Five-SNP test may predict the risk of prostate cancer http://www.medworm.com/index.php?rid=1253327&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801606%26CID%3Drss In a group of 2,893 Swedish men with prostate cancer, five gene variants plus family history accounted for 46% of cases (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1253327 Mon, 25 Feb 2008 09:29:53 +0100 1253327 Exelixis/BMS to develop XL139, hedgehog pathway inhibitor http://www.medworm.com/index.php?rid=1253326&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801604%26CID%3Drss Exelixis, Inc. and Bristol-Myers Squibb Company will collaborate to co-develop and co-commercialize Exelixis' compound XL139, a small molecule inhibitor of the hedgehog pathway, in the United States. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1253326 Mon, 25 Feb 2008 09:29:53 +0100 1253326 Rheumatoid Arthritis: Treatment of Newly Diagnosed Disease http://www.medworm.com/index.php?rid=1252902&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206503916%26CID%3Drss NSAIDs help control the pain and inflammation of rheumatoid arthritis (RA) but do not affect disease progression; they are recommended for patients with newly diagnosed RA only as an adjunct to disease-modifying antirheumatic drug (DMARD) therapy. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1252902 Sun, 24 Feb 2008 20:55:38 +0100 1252902 ONI names four deputy editors to advisory board http://www.medworm.com/index.php?rid=1252901&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801566%26CID%3Drss Oncology News International has named four deputy editors to its editorial advisory team, Editor-in-Chief Steven Rosen, MD, announced. The new deputy editors represent a spectrum of interests, including genitourinary and breast tumors, surgical oncology, and radiation oncology. Monica Bertagnolli, MD, Derek Raghavan, MD, PhD; Andrew D. Seidman, MD; Joel Tepper, MD, a radiation oncologist and professor at the University of North Carolina School of Medicine. He is a former president and chairman of the board for ASTRO and currently sits on the board of directors for ASCO. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1252901 Sun, 24 Feb 2008 20:55:38 +0100 1252901 FDA approves IV antiemetic Emend for chemo patients http://www.medworm.com/index.php?rid=1252900&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801562%26CID%3Drss A new formulation of Emend has entered oncology's antiemetic armamentarium. Emend (fosaprepitant dimeglumine, Merck) for Injection received US Food and Drug Administration approval in late January for use in combination with other antiemetic agents for the prevention of acute and delayed nausea and vomiting associated with initial and repeated courses of moderate- or high-emetogenic chemotherapies, including high-dose cisplatin. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1252900 Sun, 24 Feb 2008 20:55:38 +0100 1252900 ONI remembers Judah Folkman, founder of angiogenesis http://www.medworm.com/index.php?rid=1252899&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801561%26CID%3Drss On January 14, Dr. Judah Folkman, founder of the field of angiogenesis, died unexpectedly at age 74 in Denver, while en route to Vancouver for a lecture. Dr. Folkman was founder and director of the Vascular Biology Program at Children's Hospital, Boston, and professor of pediatric surgery and cell biology at Harvard. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1252899 Sun, 24 Feb 2008 20:55:38 +0100 1252899 NLST article not balanced, critic of screening trial asserts http://www.medworm.com/index.php?rid=1252898&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801560%26CID%3Drss "Researchers defend NLST protocol against its critics" (ONI, January 2008, page 14) quoted three individuals in the United States who strongly support the NLST [National Lung Screening Trial] and no one on the other side of the issue. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1252898 Sun, 24 Feb 2008 20:55:38 +0100 1252898 A bold proposal to streamline clinical trials http://www.medworm.com/index.php?rid=1252897&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801559%26CID%3Drss If therapeutic agents are documented to be more effective than standard therapies in the advanced breast cancer setting, they will also be effective in the adjuvant setting. This renders randomized phase III adjuvant trials unnecessary in many cases, and means that undue delays in moving new agents up-front are costing lives (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1252897 Sun, 24 Feb 2008 20:55:38 +0100 1252897 Masters of hematology/oncology ONI sits down with Dr. Vincent DeVita http://www.medworm.com/index.php?rid=1252896&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206801557%26CID%3Drss As a young boy, Vincent DeVita dissected frogs on the front steps of his parents' house in Yonkers. In the eyes of his encouraging mother, he was already a budding physician fascinated by the internal complications of life. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1252896 Sun, 24 Feb 2008 20:55:38 +0100 1252896 Woman With Edema, Vomiting, and Diarrhea http://www.medworm.com/index.php?rid=1234852&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206503934%26CID%3Drss A 22-year-old woman has had chronic nausea, emesis with green vomitus, and diarrhea for the past 10 months. The diarrhea is frequent (about 3 to 8 times daily) and does not resolve with starvation. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1234852 Fri, 15 Feb 2008 21:23:36 +0100 1234852 Middle-Aged Woman With Epistaxis, Facial Pain and Swelling, and Otalgia http://www.medworm.com/index.php?rid=1234851&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206503929%26CID%3Drss For 2 weeks, a 49-year-old woman has had mild, intermittent epistaxis with left-sided facial pain, swelling, and otalgia; the severity of the bleeding has increased during the past 24 hours. She also has congestion of the left naris of 1 month's duration. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1234851 Fri, 15 Feb 2008 21:23:36 +0100 1234851 Latest Guidelines on Community-Acquired Pneumonia: Part 2, Empirical Therapy http://www.medworm.com/index.php?rid=1234850&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206503928%26CID%3Drss New guidelines for community-acquired pneumonia (CAP) issued jointly by the Infectious Diseases Society of America and the American Thoracic Society emphasize the need for communities to adapt the recommendations to local conditions. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1234850 Fri, 15 Feb 2008 21:23:36 +0100 1234850 WIN-R Is Winning as New Protocol for Hepatitis C http://www.medworm.com/index.php?rid=1234849&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206503923%26CID%3Drss Several recent studies from Europe and the United States confirm that tailoring the dosage and duration of pegylated interferon alfa 2b and ribavirin therapy can optimize treatment of hepatitis C virus (HCV) infection. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1234849 Fri, 15 Feb 2008 21:23:36 +0100 1234849 SSRIs and Triptans: Safe as Combination Therapy? http://www.medworm.com/index.php?rid=1234848&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206503922%26CID%3Drss Depression was diagnosed 6 years earlier in a 37-year-old woman; it has been successfully managed since then with fluoxetine and outpatient psychotherapy. Since her teenage years, the patient has also experienced sporadic (fewer than 3 or 4 per year) mild or occasionally severe headaches, which she has usually self-treated with over-thecounter (OTC) agents or "just slept off." (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1234848 Fri, 15 Feb 2008 21:23:36 +0100 1234848 A Photo Quiz to Hone Dermatologic Skills http://www.medworm.com/index.php?rid=1234847&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206503920%26CID%3Drss Dermclinic (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1234847 Fri, 15 Feb 2008 21:23:36 +0100 1234847 Renal Infarction: An Unusual Complication of Cocaine Abuse http://www.medworm.com/index.php?rid=1234846&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206503919%26CID%3Drss A 63-year-old African American man presented with severe epigastric pain of 1 day's duration. The pain was sharp and continuous and radiated toward the left flank. There were no aggravating or relieving factors or previous similar episodes. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1234846 Fri, 15 Feb 2008 21:23:36 +0100 1234846 Hearts Within Hearts http://www.medworm.com/index.php?rid=1233346&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206503927%26CID%3Drss In recognition of Valentine's Day, we present 2 incidental heart-shaped findings we encountered within the hearts of 2 patients during 2-dimensional transthoracic echocardiographic studies. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1233346 Fri, 15 Feb 2008 09:16:09 +0100 1233346 Beau Lines http://www.medworm.com/index.php?rid=1233345&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206503926%26CID%3Drss Transverse depressions like the one shown here ap- peared on all the other nails of this 68-year-old man several weeks after he had suffered a myocardial infarction. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1233345 Fri, 15 Feb 2008 09:16:09 +0100 1233345 Acne Conglobata http://www.medworm.com/index.php?rid=1233344&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206503925%26CID%3Drss For 3 months, a 24-year-old man--a military aviator--had a worsening rash on his chest. He had no lesions elsewhere. Culture of the ulcers grew Pseudomonas. A 2-week course of antibiotic therapy was ineffective. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1233344 Fri, 15 Feb 2008 09:16:09 +0100 1233344 Ruptured Abdominal Aortic Aneurysm http://www.medworm.com/index.php?rid=1233343&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206503924%26CID%3Drss An obese 61-year-old man with a history of heroin abuse was brought to the hospital after he had fallen onto his buttocks on a sidewalk. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1233343 Fri, 15 Feb 2008 09:16:09 +0100 1233343 Might Rare Familial Cancer Syndrome Be Cause of Cold and Flushing? http://www.medworm.com/index.php?rid=1233342&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206503918%26CID%3Drss The recent "Consultations & Comments" exchange titled "What Cause of Cold and Flushing in a Basketball Player?" (CONSULTANT, November 2007) attracted my attention. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1233342 Fri, 15 Feb 2008 09:16:09 +0100 1233342 End-of-Life Discussions: The Art of Delivering Bad News http://www.medworm.com/index.php?rid=1233341&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206503915%26CID%3Drss An 84-year-old woman with progressive stenosis of the cervical spinal canal, type 2 diabetes mellitus, hyperlipidemia, gastroesophageal reflux disease, hypertension, and stable angina presents to her primary care physician after an appointment with the orthopedist who is monitoring her chronic degenerative joint disease. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1233341 Fri, 15 Feb 2008 09:16:09 +0100 1233341 One-Two-Three Wound Irrigation http://www.medworm.com/index.php?rid=1232080&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206503933%26CID%3Drss To irrigate a contaminated wound quickly, punch 3 holes in the lid of a 500-mL container of normal saline with a 14- or 16-gauge sterile needle. Invert the bottle and squeeze. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1232080 Thu, 14 Feb 2008 21:20:18 +0100 1232080 Shop the Perimeter http://www.medworm.com/index.php?rid=1232079&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206503932%26CID%3Drss Patients want and need information about diet. I recommend that they "shop the perimeter." (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1232079 Thu, 14 Feb 2008 21:20:18 +0100 1232079 Make 'Em Laugh http://www.medworm.com/index.php?rid=1232078&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206503931%26CID%3Drss Rather than relying on a gag or a wide-mouthed cry after otoscopy to examine a very young child's posterior pharynx, consider a happier alternative. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1232078 Thu, 14 Feb 2008 21:20:18 +0100 1232078 Out, Out, Bloody Spot! http://www.medworm.com/index.php?rid=1232077&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206503930%26CID%3Drss I have found that the best agent for removing blood from clothing is hydrogen peroxide. Apply it to the stain as soon as possible. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1232077 Thu, 14 Feb 2008 21:20:18 +0100 1232077 Chronic Cough: Seeking the Cause and the Solution http://www.medworm.com/index.php?rid=1232076&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206503921%26CID%3Drss In the vast majority of nonsmokers who are not receiving angiotensin converting-enzyme inhibitors and who have no evidence of active disease on chest radiographs, chronic cough is caused by postnasal drip syndrome (recently renamed upper airway cough syndrome [UACS]), asthma, non-asthmatic eosinophilic bronchitis, or gastroesophageal reflux disease (GERD), alone or in combination. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1232076 Thu, 14 Feb 2008 21:20:18 +0100 1232076 Treatment of MRSA Infection: Why Cultures Are Key http://www.medworm.com/index.php?rid=1232075&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206503917%26CID%3Drss Dr Thomas Fekete's recent article on emerging infections (CONSULTANT, October 2007) was timely, given recent evidence that the incidence of methicillin-resistant Staphylococcus aureus (MRSA) infection, both hospital-acquired and community-acquired, has assumed pandemic proportions. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1232075 Thu, 14 Feb 2008 21:20:18 +0100 1232075 Merck and Idera to develop TLR9 agonists for treatment of cancer http://www.medworm.com/index.php?rid=1226871&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205903821%26CID%3Drss (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1226871 Wed, 13 Feb 2008 09:26:19 +0100 1226871 Emerging Role of HIFU as a Noninvasive Ablative Method to Treat Localized Prostate Cancer http://www.medworm.com/index.php?rid=1226870&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206502345%26CID%3Drss The use of high-intensity focused ultrasound (HIFU) as a method for ablation of a localized tumor growth is not new. Several attempts have been made to apply the principles of HIFU to the treatment of pelvic, brain, and gastrointestinal tumors. However, only in the past decade has our understanding of the basic principles of HIFU allowed us to further exploit its application as a radical and truly noninvasive, intent-to-treat, ablative method for treating organ-confined prostate cancer. Prostate cancer remains an elusive disease, with many questions surrounding its natural history and the selection of appropriate patients for treatment yet to be answered. HIFU may play a crucial role in our search for an efficacious and safe primary treatment for localized prostate cancer. Its noninvasive ... ConsultantLive news http://www.medworm.com/rss/comments.php?id=1226870 Wed, 13 Feb 2008 09:26:19 +0100 1226870 New Therapeutic Options in Gastrointestinal Stromal Tumors http://www.medworm.com/index.php?rid=1226869&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206502512%26CID%3Drss Gastrointestinal stromal tumors have until recently had a uniformly poor prognosis with lack of effective drug therapies. These tumors usually have activating mutations in either KIT or PDGFR-α tyrosine kinase receptors. Over the past decade, imatinib (Gleevec), a selective tyrosine kinase inhibitor has become the standard of care for the first-line treatment of patients with unresectable and metastatic disease. For patients with imatinib-resistant disease or intolerant to the side effects of imatinib, sunitinib (Sutent), a multitargeted tyrosine kinase inhibitor was recently approved. For earlier-stage disease, status post–complete surgical excision, preliminary data seem encouraging for the role of adjuvant imatinib in prolonging patients' disease-free interval. The impact of... ConsultantLive news http://www.medworm.com/rss/comments.php?id=1226869 Wed, 13 Feb 2008 09:26:19 +0100 1226869 Priority Review Granted for Peginterferon Alfa-2b to Treat Stage III Melanoma http://www.medworm.com/index.php?rid=1226868&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206502499%26CID%3Drss US Food and Drug Administration (FDA) has accepted the peginterferon alfa-2b (PEG-Intron) supplemental Biologics License Application (sBLA) for for review and has granted Priority Review status to the drug for the adjuvant treatment of patients with stage III melanoma (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1226868 Wed, 13 Feb 2008 09:26:19 +0100 1226868 Regulatory Status of the Buccal Fentanyl sNDA Updated http://www.medworm.com/index.php?rid=1226867&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206502498%26CID%3Drss US Food and Drug Administration (FDA) has accepted Cephalon's supplemental New Drug Application (sNDA) for fentanyl buccal tablets (Fentora) for the management of breakthrough pain in opioid-tolerant patients with chronic pain. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1226867 Wed, 13 Feb 2008 09:26:19 +0100 1226867 FDA Grants Priority Review for Bortezomib in Newly Diagnosed Multiple Myeloma http://www.medworm.com/index.php?rid=1226866&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206502485%26CID%3Drss US Food and Drug Administration (FDA) granted priority review for bortezomib (Velcade) in patients with newly diagnosed multiple myeloma (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1226866 Wed, 13 Feb 2008 09:26:19 +0100 1226866 Systemic Therapy for Lung Cancer Brain Metastases: A Rationale for Clinical Trials http://www.medworm.com/index.php?rid=1226865&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206502484%26CID%3Drss Despite the high prevalence of brain metastases in patients with metastatic lung cancer, these patients have been excluded from enrollment in clinical trials of new therapeutic drugs. The reasons for exclusion have centered on concerns that the blood-brain barrier may impede drug delivery into brain metastases, that brain metastases confer a dismal survival for metastatic lung cancer patients, and that brain metastases carry risk for cerebrovascular hemorrhage. A focused, updated review of these issues, however, clearly shows that these particular concerns are unwarranted. An extensive review of clinical trials on the efficacy of chemotheraputic agents against lung cancer brain metastases is also provided. This collective information describes an area in need of therapeutic development and... ConsultantLive news http://www.medworm.com/rss/comments.php?id=1226865 Wed, 13 Feb 2008 09:26:19 +0100 1226865 Systemic Therapy for Lung Cancer Brain Metastases: A Rationale for Clinical Trials http://www.medworm.com/index.php?rid=1226864&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206502471%26CID%3Drss Despite the high prevalence of brain metastases in patients with metastatic lung cancer, these patients have been excluded from enrollment in clinical trials of new therapeutic drugs. The reasons for exclusion have centered on concerns that the blood-brain barrier may impede drug delivery into brain metastases, that brain metastases confer a dismal survival for metastatic lung cancer patients, and that brain metastases carry risk for cerebrovascular hemorrhage. A focused, updated review of these issues, however, clearly shows that these particular concerns are unwarranted. An extensive review of clinical trials on the efficacy of chemotheraputic agents against lung cancer brain metastases is also provided. This collective information describes an area in need of therapeutic development and... ConsultantLive news http://www.medworm.com/rss/comments.php?id=1226864 Wed, 13 Feb 2008 09:26:19 +0100 1226864 Management of Pain in the Older Person With Cancer http://www.medworm.com/index.php?rid=1226863&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206502458%26CID%3Drss Pain in older cancer patients is a common event, and many times it is undertreated. Barriers to cancer pain management in the elderly include concerns about the use of medications, the atypical manifestations of pain in the elderly, and side effects related to opioid and other analgesic drugs. The care of older cancer patients experiencing pain involves a comprehensive assessment, which includes evaluation for conditions that may exacerbate or be exacerbated by pain, affecting its expression, such as emotional and spiritual distress, disability, and comorbid conditions. It is important to use appropriate tools to evaluate pain and other symptoms that can be related to it. Pain in older cancer patients should be managed in an interdisciplinary environment using pharmacologic and nonpharmaco... ConsultantLive news http://www.medworm.com/rss/comments.php?id=1226863 Wed, 13 Feb 2008 09:26:19 +0100 1226863 Management of Pain in the Older Person With Cancer http://www.medworm.com/index.php?rid=1226862&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206502457%26CID%3Drss Pain in older cancer patients is a common event, and many times it is undertreated. Barriers to cancer pain management in the elderly include concerns about the use of medications, the atypical manifestations of pain in the elderly, and side effects related to opioid and other analgesic drugs. The care of older cancer patients experiencing pain involves a comprehensive assessment, which includes evaluation for conditions that may exacerbate or be exacerbated by pain, affecting its expression, such as emotional and spiritual distress, disability, and comorbid conditions. It is important to use appropriate tools to evaluate pain and other symptoms that can be related to it. Pain in older cancer patients should be managed in an interdisciplinary environment using pharmacologic and nonpharmaco... ConsultantLive news http://www.medworm.com/rss/comments.php?id=1226862 Wed, 13 Feb 2008 09:26:19 +0100 1226862 Management of Pain in the Older Person With Cancer http://www.medworm.com/index.php?rid=1226861&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206502432%26CID%3Drss Pain in older cancer patients is a common event, and many times it is undertreated. Barriers to cancer pain management in the elderly include concerns about the use of medications, the atypical manifestations of pain in the elderly, and side effects related to opioid and other analgesic drugs. The care of older cancer patients experiencing pain involves a comprehensive assessment, which includes evaluation for conditions that may exacerbate or be exacerbated by pain, affecting its expression, such as emotional and spiritual distress, disability, and comorbid conditions. It is important to use appropriate tools to evaluate pain and other symptoms that can be related to it. Pain in older cancer patients should be managed in an interdisciplinary environment using pharmacologic and nonpharmaco... ConsultantLive news http://www.medworm.com/rss/comments.php?id=1226861 Wed, 13 Feb 2008 09:26:19 +0100 1226861 Mayo Clinic Study Finds Further Association Between Diabetes and Pancreatic Cancer http://www.medworm.com/index.php?rid=1226860&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206502419%26CID%3Drss new Mayo Clinic study found that 40% of pancreatic cancer patients are diagnosed with diabetes prior to their pancreatic cancer diagnosis (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1226860 Wed, 13 Feb 2008 09:26:19 +0100 1226860 Biomarker CCSA-2 May Provide Accurate Blood Test for Colorectal Cancer http://www.medworm.com/index.php?rid=1226859&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206502406%26CID%3Drss blood-based marker called colon cancer–specific antigen-2 (CCSA-2) may be an accurate indicator of colorectal cancer (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1226859 Wed, 13 Feb 2008 09:26:19 +0100 1226859 Emerging Role of HIFU as a Noninvasive Ablative Method to Treat Localized Prostate Cancer http://www.medworm.com/index.php?rid=1226858&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206502404%26CID%3Drss The use of high-intensity focused ultrasound (HIFU) as a method for ablation of a localized tumor growth is not new. Several attempts have been made to apply the principles of HIFU to the treatment of pelvic, brain, and gastrointestinal tumors. However, only in the past decade has our understanding of the basic principles of HIFU allowed us to further exploit its application as a radical and truly noninvasive, intent-to-treat, ablative method for treating organ-confined prostate cancer. Prostate cancer remains an elusive disease, with many questions surrounding its natural history and the selection of appropriate patients for treatment yet to be answered. HIFU may play a crucial role in our search for an efficacious and safe primary treatment for localized prostate cancer. Its noninvasive ... ConsultantLive news http://www.medworm.com/rss/comments.php?id=1226858 Wed, 13 Feb 2008 09:26:19 +0100 1226858 Emerging Role of HIFU as a Noninvasive Ablative Method to Treat Localized Prostate Cancer http://www.medworm.com/index.php?rid=1226857&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206502362%26CID%3Drss The use of high-intensity focused ultrasound (HIFU) as a method for ablation of a localized tumor growth is not new. Several attempts have been made to apply the principles of HIFU to the treatment of pelvic, brain, and gastrointestinal tumors. However, only in the past decade has our understanding of the basic principles of HIFU allowed us to further exploit its application as a radical and truly noninvasive, intent-to-treat, ablative method for treating organ-confined prostate cancer. Prostate cancer remains an elusive disease, with many questions surrounding its natural history and the selection of appropriate patients for treatment yet to be answered. HIFU may play a crucial role in our search for an efficacious and safe primary treatment for localized prostate cancer. Its noninvasive ... ConsultantLive news http://www.medworm.com/rss/comments.php?id=1226857 Wed, 13 Feb 2008 09:26:19 +0100 1226857 Emerging Role of HIFU as a Noninvasive Ablative Method to Treat Localized Prostate Cancer http://www.medworm.com/index.php?rid=1226856&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206502347%26CID%3Drss The use of high-intensity focused ultrasound (HIFU) as a method for ablation of a localized tumor growth is not new. Several attempts have been made to apply the principles of HIFU to the treatment of pelvic, brain, and gastrointestinal tumors. However, only in the past decade has our understanding of the basic principles of HIFU allowed us to further exploit its application as a radical and truly noninvasive, intent-to-treat, ablative method for treating organ-confined prostate cancer. Prostate cancer remains an elusive disease, with many questions surrounding its natural history and the selection of appropriate patients for treatment yet to be answered. HIFU may play a crucial role in our search for an efficacious and safe primary treatment for localized prostate cancer. Its noninvasive ... ConsultantLive news http://www.medworm.com/rss/comments.php?id=1226856 Wed, 13 Feb 2008 09:26:19 +0100 1226856 Treatment of GIST: Clarifying the Data http://www.medworm.com/index.php?rid=1226855&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206502516%26CID%3Drss Gastrointestinal stromal tumors have until recently had a uniformly poor prognosis with lack of effective drug therapies. These tumors usually have activating mutations in either KIT or PDGFR-α tyrosine kinase receptors. Over the past decade, imatinib (Gleevec), a selective tyrosine kinase inhibitor has become the standard of care for the first-line treatment of patients with unresectable and metastatic disease. For patients with imatinib-resistant disease or intolerant to the side effects of imatinib, sunitinib (Sutent), a multitargeted tyrosine kinase inhibitor was recently approved. For earlier-stage disease, status post–complete surgical excision, preliminary data seem encouraging for the role of adjuvant imatinib in prolonging patients' disease-free interval. The impact of... ConsultantLive news http://www.medworm.com/rss/comments.php?id=1226855 Wed, 13 Feb 2008 09:26:19 +0100 1226855 Emerging Role of HIFU as a Noninvasive Ablative Method to Treat Localized Prostate Cancer http://www.medworm.com/index.php?rid=1226854&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D206502257%26CID%3Drss The use of high-intensity focused ultrasound (HIFU) as a method for ablation of a localized tumor growth is not new. Several attempts have been made to apply the principles of HIFU to the treatment of pelvic, brain, and gastrointestinal tumors. However, only in the past decade has our understanding of the basic principles of HIFU allowed us to further exploit its application as a radical and truly noninvasive, intent-to-treat, ablative method for treating organ-confined prostate cancer. Prostate cancer remains an elusive disease, with many questions surrounding its natural history and the selection of appropriate patients for treatment yet to be answered. HIFU may play a crucial role in our search for an efficacious and safe primary treatment for localized prostate cancer. Its noninvasive ... ConsultantLive news http://www.medworm.com/rss/comments.php?id=1226854 Wed, 13 Feb 2008 09:26:19 +0100 1226854 CMS policy drives fall in ESA use http://www.medworm.com/index.php?rid=1170260&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205903467%26CID%3Drss Mounting evidence suggests that a 2007 Medicare coverage decision has severely curtailed the use of ESAs for chemotherapy-induced anemia. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1170260 Wed, 23 Jan 2008 12:04:48 +0100 1170260 Sunesis and MMRC collaborate to study SNS-032 in myeloma http://www.medworm.com/index.php?rid=1170259&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205903820%26CID%3Drss (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1170259 Wed, 23 Jan 2008 12:04:48 +0100 1170259 First phase III trial of Zactima in NSCLC completes enrollment http://www.medworm.com/index.php?rid=1170258&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205903819%26CID%3Drss (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1170258 Wed, 23 Jan 2008 12:04:48 +0100 1170258 Good results with multicatheter brachytherapy APBI http://www.medworm.com/index.php?rid=1170257&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205903799%26CID%3Drss Use of accelerated partial breast irradiation (APBI) with multicatheter brachytherapy to treat resected early-stage breast cancer is associated with good early outcomes in terms of local control, adverse effects, and cosmesis (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1170257 Wed, 23 Jan 2008 12:04:48 +0100 1170257 Statins during RT may lower risk of prostate ca relapse http://www.medworm.com/index.php?rid=1167313&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205903778%26CID%3Drss Men who have undergone high-dose radiation therapy for prostate cancer have a reduced risk of relapse if they were taking statins during their radiation therapy (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1167313 Tue, 22 Jan 2008 11:14:02 +0100 1167313 Concurrent chemotherapy-PBI feasible with low toxicity http://www.medworm.com/index.php?rid=1167312&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205903777%26CID%3Drss Partial breast irradiation (PBI) with concurrent chemotherapy is feasible and is associated with an acceptable rate of toxicity (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1167312 Tue, 22 Jan 2008 11:14:02 +0100 1167312 Breast MRI reveals occult cancers in PBI candidates http://www.medworm.com/index.php?rid=1167311&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205903776%26CID%3Drss Breast MRI identifies mammographically occult secondary tumors in about 6% of women with early-stage breast cancer who would otherwise qualify for partial breast irradiation (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1167311 Tue, 22 Jan 2008 11:14:02 +0100 1167311 Zevalin boosts PFS in advanced follicular NHL patients http://www.medworm.com/index.php?rid=1167310&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205903756%26CID%3Drss Consolidation therapy using Zevalin (90yttrium-ibritumomab tiuxetan) following first remission significantly extends progression-free survival in patients with advanced-stage follicular non-Hodgkin's lymphoma (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1167310 Tue, 22 Jan 2008 11:14:02 +0100 1167310 PET provides clues to improving lung cancer radiotherapy http://www.medworm.com/index.php?rid=1167309&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205903755%26CID%3Drss Positron emission tomography (PET) can be used to better characterize patterns of local failure after definitive radiation therapy for non-small-cell lung cancer, which may help to improve that therapy (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1167309 Tue, 22 Jan 2008 11:14:02 +0100 1167309 Cetuximab efficacy does not vary with EGFR expression http://www.medworm.com/index.php?rid=1167308&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205903735%26CID%3Drss The efficacy of cetuximab (Erbitux) plus chemoradiation in patients with locally advanced non-small-cell lung cancer does not appear to vary with the tumor's epidermal growth factor receptor expression, according to preliminary results of a phase II trial (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1167308 Tue, 22 Jan 2008 11:14:02 +0100 1167308 High cost of breast MRI screening appears to be justified http://www.medworm.com/index.php?rid=1167307&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205903732%26CID%3Drss MRI has outrun other modalities in a screening trial involving high-risk women. Such research helps justify an estimated $1.4 billion a year in direct costs for the United States if new American Cancer Society guidelines (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1167307 Tue, 22 Jan 2008 11:14:02 +0100 1167307 Microarray technology aids in breast ca prognosis http://www.medworm.com/index.php?rid=1167306&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205903731%26CID%3Drss A cutting-edge prognostic tool called MammaPrint, developed by Agendia, a laboratory located in The Netherlands, uses molecular technology to predict whether breast cancer will metastasize, helping clinicians make more accurate management decisions for their patients. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1167306 Tue, 22 Jan 2008 11:14:02 +0100 1167306 Texas voters listen to Lance http://www.medworm.com/index.php?rid=1167305&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205903730%26CID%3Drss Proposition 15, which passed by a margin of 61% to 39% last November, provides for the creation of the Cancer Prevention and Research Institute of Texas and authorizes issuance of up to $3 billion in bonds for research in Texas to find the causes of and cures for cancer. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1167305 Tue, 22 Jan 2008 11:14:02 +0100 1167305 Call for congressional hearing on Provenge approval process re-ignites FDA conflict-of-interest controversy http://www.medworm.com/index.php?rid=1167304&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205903710%26CID%3Drss A call for a congressional hearing has put the FDA drug approval process under scrutiny for possible conflict-of-interest vio-lations. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1167304 Tue, 22 Jan 2008 11:14:02 +0100 1167304 High-dose neoadjuvant fulvestrant tested http://www.medworm.com/index.php?rid=1167303&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205903709%26CID%3Drss In the neoadju-vant treatment of early breast cancer, fulvestrant (Faslodex) 500 mg effected a greater reduction in biomarkers of proliferation and produced more responses than the standard 250 mg dose (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1167303 Tue, 22 Jan 2008 11:14:02 +0100 1167303 Xeloda/Ixempra effective in resistant triple-negative ca http://www.medworm.com/index.php?rid=1167302&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205903697%26CID%3Drss The combination of capecitabine (Xeloda) and ixabepilone (Ixempra) appears to be robust in patients with the so-called triple-negative breast cancer phenotype (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1167302 Tue, 22 Jan 2008 11:14:02 +0100 1167302 Major policy issue lies behind ODAC's Avastin decision http://www.medworm.com/index.php?rid=1167301&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205903688%26CID%3Drss By a 5-4 vote, the Oncology Drugs Advisory Committee failed to recommend that FDA approve Avastin (bevacizumab, Genentech) in combination with paclitaxel as a first-line treatment for locally recurrent or metastatic, HER2-negative breast cancer. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1167301 Tue, 22 Jan 2008 11:14:02 +0100 1167301 Black raspberries may protect against esophageal ca http://www.medworm.com/index.php?rid=1167300&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205903687%26CID%3Drss Extracts of black raspberries might protect Barrett's esophagus patients against esophageal cancer and also might shift premalignant oral lesions from progression to squamous cell carcinoma (SCC) back toward normal differentiation (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1167300 Tue, 22 Jan 2008 11:14:02 +0100 1167300 Broccoli sprouts extract might lower bladder cancer risk http://www.medworm.com/index.php?rid=1167299&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205903667%26CID%3Drss Eating a concentrated extract of freeze-dried broccoli sprouts might inhibit bladder cancer by delivering a protective factor right where the bladder is most at risk. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1167299 Tue, 22 Jan 2008 11:14:02 +0100 1167299 African Americans have higher risk of relapse after BCT http://www.medworm.com/index.php?rid=1167298&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205903666%26CID%3Drss African-American women with early-stage breast cancer are more likely than their Caucasian counterparts to experience a relapse after breast-conserving therapy, but the absolute difference in risk is small (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1167298 Tue, 22 Jan 2008 11:14:02 +0100 1167298 New tobacco product alert: Camel Snus is on the loose http://www.medworm.com/index.php?rid=1167297&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205903646%26CID%3Drss Imagine my surprise to unwrap my Sunday paper one day last month and find inside a clever advertising pamphlet and a card good for a free tin of Camel Snus (pronounced "snoose"), R.J. Reynolds' new flavored spitless chewing tobacco. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1167297 Tue, 22 Jan 2008 11:14:02 +0100 1167297 Diagnostic Dilemma: GI Disease http://www.medworm.com/index.php?rid=1167296&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205903626%26CID%3Drss A 68-year-old man with a history of small-cell lung cancer with bony metastases was admitted with diarrhea. The patient had completed chemotherapy one week earlier with cisplatin and etoposide, along with radiation therapy, and irinotecan (Camptosar). The patient was found to be neutropenic. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1167296 Tue, 22 Jan 2008 11:14:02 +0100 1167296 RT improves outcomes of early-stage DLBCL patients http://www.medworm.com/index.php?rid=1167295&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205903566%26CID%3Drss Patients with early-stage diffuse large B-cell lymphoma (DLBCL) have improved long-term disease-free and overall survival if their first-line treatment includes radiation therapy, according to the largest outcomes study to date among this population. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1167295 Tue, 22 Jan 2008 11:14:02 +0100 1167295 Dasatinib promising as induction therapy of Ph+ ALL http://www.medworm.com/index.php?rid=1167294&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205903605%26CID%3Drss The first interim results from the first study of dasatinib (Sprycel) as induction therapy of Ph+ acute lymphoblastic leukemia (ALL) show complete and early hematologic responses with good overall compliance (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1167294 Tue, 22 Jan 2008 11:14:02 +0100 1167294 Cellectar opens manufacturing facility for radiolabeled CLR1404 http://www.medworm.com/index.php?rid=1162883&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205903841%26CID%3Drss (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1162883 Sun, 20 Jan 2008 09:58:17 +0100 1162883 Anthracyclines in early breast ca: Is the end near? http://www.medworm.com/index.php?rid=1162664&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205903487%26CID%3Drss Studies presented at the 2007 San Antonio Breast Cancer Symposium raise new questions about the role of anthracycline-based regimens as adjuvant therapy in early breast cancer, suggesting that these regimens may be appropriate only for a small subset of patients. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1162664 Sat, 19 Jan 2008 22:34:59 +0100 1162664 Cost-shifting could sink healthcare system http://www.medworm.com/index.php?rid=1162081&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205901888%26CID%3Drss Soaring expenditures must be contained or they will end up sinking the healthcare system, Allen S. Lichter, MD, CEO of ASCO, said during a featured appearance at the Radiological Society of North America meeting (see photograph below). Among the changes that could help attack the problem is mandatory insurance coverage for all citizens, Dr. Lichter said. He also cast doubt on the ability of one currently popular approach, consumer-driven, high-deductible healthcare plans, to solve the system's problems. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1162081 Sat, 19 Jan 2008 09:54:24 +0100 1162081 Management of Pain in the Older Person With Cancer http://www.medworm.com/index.php?rid=1159609&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205900696%26CID%3Drss Pain in older cancer patients is a common event, and many times it is undertreated. Barriers to cancer pain management in the elderly include concerns about the use of medications, the atypical manifestations of pain in the elderly, and side effects related to opioid and other analgesic drugs. The care of older cancer patients experiencing pain involves a comprehensive assessment, which includes evaluation for conditions that may exacerbate or be exacerbated by pain, affecting its expression, such as emotional and spiritual distress, disability, and comorbid conditions. It is important to use appropriate tools to evaluate pain and other symptoms that can be related to it. Pain in older cancer patients should be managed in an interdisciplinary environment using pharmacologic and nonpharmaco... ConsultantLive news http://www.medworm.com/rss/comments.php?id=1159609 Fri, 18 Jan 2008 10:12:27 +0100 1159609 Capecitabine-Based Combination Proves Comparable to Standard Therapy in Esophagogastric Cancer http://www.medworm.com/index.php?rid=1159608&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205900695%26CID%3Drss Data published in the New England Journal of Medicine show that oral capecitabine (Xeloda) and oxaliplatin (Eloxatin) in combination with epirubicin (Ellence) is a comparable alternative to infused fluorouracil (5-FU) and cisplatin with epirubicin in patients with previously untreated, advanced esophagogastric cancer. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1159608 Fri, 18 Jan 2008 10:12:27 +0100 1159608 Anastrozole Confirmed Superior in Breast Cancer Prevention http://www.medworm.com/index.php?rid=1159607&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205900683%26CID%3Drss Anastrozole (Arimidex) is more effective than tamoxifen at preventing breast cancer recurrence for periods of at least 10 years in women with hormone-responsive cancers. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1159607 Fri, 18 Jan 2008 10:12:27 +0100 1159607 Radiation-Induced Lung Injury http://www.medworm.com/index.php?rid=1159606&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205900682%26CID%3Drss Radiation therapy (RT) is an important treatment modality for multiple thoracic malignancies. Incidental irradiation of the lungs, which are particularly susceptible to injury, is unavoidable and often dose-limiting. The most radiosensitive subunit of the lung is the alveolar/capillary complex, and RT-induced lung injury is often described as diffuse alveolar damage. Reactive oxygen species generated by RT are directly toxic to parenchymal cells and initiate a cascade of molecular events that alter the cytokine milieu of the microenvironment, creating a self-sustaining cycle of inflammation and chronic oxidative stress. Replacement of normal lung parenchyma by fibrosis is the culminating event. Depending on the dose and volume of lung irradiated, acute radiation pneumonitis may develop, ch... ConsultantLive news http://www.medworm.com/rss/comments.php?id=1159606 Fri, 18 Jan 2008 10:12:27 +0100 1159606 Radiation-Induced Lung Injury http://www.medworm.com/index.php?rid=1159605&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205900670%26CID%3Drss Radiation therapy (RT) is an important treatment modality for multiple thoracic malignancies. Incidental irradiation of the lungs, which are particularly susceptible to injury, is unavoidable and often dose-limiting. The most radiosensitive subunit of the lung is the alveolar/capillary complex, and RT-induced lung injury is often described as diffuse alveolar damage. Reactive oxygen species generated by RT are directly toxic to parenchymal cells and initiate a cascade of molecular events that alter the cytokine milieu of the microenvironment, creating a self-sustaining cycle of inflammation and chronic oxidative stress. Replacement of normal lung parenchyma by fibrosis is the culminating event. Depending on the dose and volume of lung irradiated, acute radiation pneumonitis may develop, ch... ConsultantLive news http://www.medworm.com/rss/comments.php?id=1159605 Fri, 18 Jan 2008 10:12:27 +0100 1159605 What Is the Role of Maintenance Rituximab in Follicular NHL? http://www.medworm.com/index.php?rid=1159604&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205900662%26CID%3Drss This article discusses the risks and benefits of maintenance rituximab for follicular NHL. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1159604 Fri, 18 Jan 2008 10:12:27 +0100 1159604 What Is the Role of Maintenance Rituximab in Follicular NHL? http://www.medworm.com/index.php?rid=1159603&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205900659%26CID%3Drss This article discusses the risks and benefits of maintenance rituximab for follicular NHL. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1159603 Fri, 18 Jan 2008 10:12:27 +0100 1159603 Oblimersen Plus Chemotherapy Prolongs Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete Remission http://www.medworm.com/index.php?rid=1159602&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205900769%26CID%3Drss Genta Incorporated announced the release of new survival analyses based on extended follow-up of patients in a randomized phase III trial of oblimersen sodium (Genasense) for relapsed or refractory chronic lymphocytic leukemia (CLL). (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1159602 Fri, 18 Jan 2008 10:12:27 +0100 1159602 ONCOLOGY: A Look Ahead http://www.medworm.com/index.php?rid=1159601&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205900627%26CID%3Drss This month ONCOLOGY enters its 22nd year of publication as the preeminent journal for review articles offering you relevant, practical, and indexed oncology literature. We look forward to sharing a number of important announcements and plans for the year ahead, with new clinical features developed in response to your feedback during focus groups, online surveys, and questionnaires conducted over the past year. First, however, some exciting news... Nancy E. Davidson Appointed Co-Editor-in-Chief (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1159601 Fri, 18 Jan 2008 10:12:27 +0100 1159601 The Pathways of Tomorrow: What Does the Future Hold for the Treatment of Colorectal Cancer? http://www.medworm.com/index.php?rid=1131242&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205208602%26CID%3Drss (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1131242 Sat, 05 Jan 2008 12:42:23 +0100 1131242 Emphysematous Pyelitis http://www.medworm.com/index.php?rid=1122576&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D175007670%26CID%3Drss An obese 55-year-old woman had intermittent dysuria and frequent urination for 4 days and fever, abdominal pain, and vomiting for 3 days. Her history included type 1 diabetes mellitus, hypertension, and angina; her medications included insulin, nifedipine, and nitroglycerin. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1122576 Mon, 31 Dec 2007 13:20:00 +0100 1122576 Optimizing the Use of Tamoxifen and Aromatase Inhibitors in Early Breast Cancer http://www.medworm.com/index.php?rid=1120926&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205204244%26CID%3Drss In this latest installment in the E-Updates series of educational programs, Dr. Hyman Muss, of the University of Vermont College of Medicine and the Vermont Cancer Center, presents eight important abstracts on optimizing the use of tamoxifen and aromatase inhibitors in early breast cancer that were presented at three recent major breast cancer meetings. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1120926 Sat, 29 Dec 2007 02:05:20 +0100 1120926 CT-related radiation blamed for up to 2% of US cancers http://www.medworm.com/index.php?rid=1112755&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D205200489%26CID%3Drss A New England Journal of Medicine review article is highlighting the cancer risks of computed tomography at the same time that hundreds of scientific presentations and new product announcements at the 2007 RSNA meeting are fueling the continued growth of multislice CT. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1112755 Sat, 22 Dec 2007 14:06:33 +0100 1112755 Combination of Capecitabine and Ixabepilone Proves Effective in Resistant Triple-Negative Breast Cancer http://www.medworm.com/index.php?rid=1100349&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204805529%26CID%3Drss The combination of capecitabine (Xeloda) and ixabepilone (Ixempra) appears to be robust in patients with the triple-negative breast cancer phenotype. In heavily pretreated metastatic breast cancer patients, the regimen yielded an overall response rate of 27% and median progression-free survival of 4.1 months, according to a subset analysis of 187 patients from a larger randomized phase III trial of capecitabine with and without ixabepilone. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1100349 Tue, 18 Dec 2007 02:30:52 +0100 1100349 100-Month Update Shows Continued Benefit for Anastrozole Over Tamoxifen http://www.medworm.com/index.php?rid=1100348&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204805336%26CID%3Drss A median follow-up of 100 months has shown continued benefit for anastrozole (Arimidex) as compared with tamoxifen in a study of postmenopausal women with hormone receptor-positive tumors. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1100348 Tue, 18 Dec 2007 02:30:52 +0100 1100348 Optimal Tumor Control in HER2-Positive Tumors Requires Complete Blockade http://www.medworm.com/index.php?rid=1100347&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204805400%26CID%3Drss The HER network is robust, complex, redundant, and adaptable. It provides proliferation and survival signals to a subset of breast tumors. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1100347 Tue, 18 Dec 2007 02:30:52 +0100 1100347 Isolated Tumor Cells, Micrometastases in Sentinel Nodes Fail to Affect Outcomes http://www.medworm.com/index.php?rid=1100346&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204805457%26CID%3Drss Breast cancer patients with isolated tumor cells or micrometastases in sentinel nodes do not have poorer disease-free or overall survival than their counterparts with negative sentinel nodes, researchers reported at the SABCS (abstract 52). (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1100346 Tue, 18 Dec 2007 02:30:52 +0100 1100346 New Genomic Assays May Help Individualize Breast Cancer Treatment http://www.medworm.com/index.php?rid=1100345&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204805361%26CID%3Drss Two new genomic assays may provide prognostic and predictive information for individual patients with breast cancer, thereby helping to guide treatment decisions, according to data from a pair of studies presented at SABCS. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1100345 Tue, 18 Dec 2007 02:30:52 +0100 1100345 Combination of http://www.medworm.com/index.php?rid=1100344&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204805631%26CID%3Drss The combination of nab-paclitaxel (Abraxane) and bevacizumab (Avastin) eradicates highly aggressive metastatic breast cancer in a preclinical model, Sophia Ran, PhD, reported at the SABCS (abstract 74). (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1100344 Tue, 18 Dec 2007 02:30:52 +0100 1100344 Early Results Suggest Small Benefit of Longer Tamoxifen Therapy http://www.medworm.com/index.php?rid=1100343&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204805322%26CID%3Drss Women with breast cancer who take adjuvant tamoxifen for 10 years have a lower risk of recurrence than their counterparts who take it for 5 years, although the difference is thus far small, according to early results of the ATLAS (Adjuvant Tamoxifen, Longer Against Shorter) trial presented at SABCS (abstract 48). (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1100343 Tue, 18 Dec 2007 02:30:52 +0100 1100343 I-SPY Trial Characterizes Tumor Biology and Response to Neoadjuvant Chemotherapy http://www.medworm.com/index.php?rid=1100342&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204805558%26CID%3Drss Preliminary findings from the I-SPY trial of neoadjuvant chemotherapy are a testament to the complexity and heterogeneity of locally advanced tumors and validate the concept that "biology should dictate the 'what' and the 'how' of treatment," according to Laura Esserman, MD, Director of the Breast Cancer Center and Professor of Surgery and Radiation at the University of California, San Francisco School of Medicine. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1100342 Tue, 18 Dec 2007 02:30:52 +0100 1100342 Efficacy of Screening in Women at High Risk: Dutch MRI Screening Study Update http://www.medworm.com/index.php?rid=1100341&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204805434%26CID%3Drss More data have emerged to suggest that MRI is more sensitive than mammography, though less specific, in screening women at high risk for breast cancer occurrence. Moreover, annual screening picks up a high number of ductal carcinomas in situ (DCIS), but also identifies tumors that are already large at diagnosis among BRCA1 mutation carriers. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1100341 Tue, 18 Dec 2007 02:30:52 +0100 1100341 Denosumab Attenuates Bone Loss Associated with Aromatase Inhibitors http://www.medworm.com/index.php?rid=1100340&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204805419%26CID%3Drss Investigational agent denosumab is safe and efficacious for attenuating bone loss among women taking adjuvant aromatase inhibitors for breast cancer, according to a phase III randomized double-blind placebo-controlled trial reported at SABCS (abstract 47). (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1100340 Tue, 18 Dec 2007 02:30:52 +0100 1100340 Some Patients with Positive Sentinel Nodes May Not Need Axillary Dissection http://www.medworm.com/index.php?rid=1100339&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204805647%26CID%3Drss Some breast cancer patients with positive sentinel lymph nodes have factors associated with a low probability of having any other positive nodes and may therefore be able to safely skip completion axillary dissection, new data show. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1100339 Tue, 18 Dec 2007 02:30:52 +0100 1100339 Hyperthermia/Chemotherapy Combination Doubles Survival in Sarcoma Patients http://www.medworm.com/index.php?rid=1098925&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204804738%26CID%3Drss Several phase III clinical studies have shown significantly better results in treating certain cancers when hyperthermia therapy was added to radiation therapy, as compared to radiation treatments alone. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1098925 Mon, 17 Dec 2007 15:03:56 +0100 1098925 Management of the Frail Elderly With Breast Cancer http://www.medworm.com/index.php?rid=1098924&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204804737%26CID%3Drss By the year 2030 most patients with breast cancer will be aged 65 years or more and many will be frail. Frailty implies diminished physiologic reserve; contributors include diminished organ function, comorbidities, impaired physical function, and geriatric syndromes. Time-efficient tools for assessing frailty are being developed and, once validated, can be used to identify frail cancer patients and help direct therapy. Screening mammography in frail patients is questionable, and a clinical breast exam is likely to identify breast cancers that warrant intervention. Hormonal therapy may be a reasonable primary therapy in older frail women with hormone receptor–positive lesions. For estrogen receptor– and progesterone receptor–negative lesions, excision of the primary tumor ... ConsultantLive news http://www.medworm.com/rss/comments.php?id=1098924 Mon, 17 Dec 2007 15:03:56 +0100 1098924 Management of the Frail Elderly With Breast Cancer http://www.medworm.com/index.php?rid=1098923&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204804726%26CID%3Drss By the year 2030 most patients with breast cancer will be aged 65 years or more and many will be frail. Frailty implies diminished physiologic reserve; contributors include diminished organ function, comorbidities, impaired physical function, and geriatric syndromes. Time-efficient tools for assessing frailty are being developed and, once validated, can be used to identify frail cancer patients and help direct therapy. Screening mammography in frail patients is questionable, and a clinical breast exam is likely to identify breast cancers that warrant intervention. Hormonal therapy may be a reasonable primary therapy in older frail women with hormone receptor–positive lesions. For estrogen receptor– and progesterone receptor–negative lesions, excision of the primary tumor ... ConsultantLive news http://www.medworm.com/rss/comments.php?id=1098923 Mon, 17 Dec 2007 15:03:56 +0100 1098923 Erlotinib/Gemcitabine for First-Line Treatment of Locally Advanced or Metastatic Adenocarcinoma of the Pancreas http://www.medworm.com/index.php?rid=1098922&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204804323%26CID%3Drss In this report, we present the pivotal study that led to the approval of erlotinib in combination with gemcitabine (Gemzar) in patients with locally advanced/metastatic chemonaive pancreatic cancer patients. The combination demonstrated a statistically significant increase in overall survival accompanied by an increase in toxicity. Physicians and patients now have a new option for the treatment of locally advanced/metastatic adenocarcinoma of the pancreas. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1098922 Mon, 17 Dec 2007 15:03:56 +0100 1098922 Erlotinib/Gemcitabine for First-Line Treatment of Locally Advanced or Metastatic Adenocarcinoma of the Pancreas http://www.medworm.com/index.php?rid=1098921&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204804322%26CID%3Drss In this report, we present the pivotal study that led to the approval of erlotinib in combination with gemcitabine (Gemzar) in patients with locally advanced/metastatic chemonaive pancreatic cancer patients. The combination demonstrated a statistically significant increase in overall survival accompanied by an increase in toxicity. Physicians and patients now have a new option for the treatment of locally advanced/metastatic adenocarcinoma of the pancreas. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1098921 Mon, 17 Dec 2007 15:03:56 +0100 1098921 Erlotinib/Gemcitabine for First-Line Treatment of Locally Advanced or Metastatic Adenocarcinoma of the Pancreas http://www.medworm.com/index.php?rid=1098920&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204804311%26CID%3Drss In this report, we present the pivotal study that led to the approval of erlotinib in combination with gemcitabine (Gemzar) in patients with locally advanced/metastatic chemonaive pancreatic cancer patients. The combination demonstrated a statistically significant increase in overall survival accompanied by an increase in toxicity. Physicians and patients now have a new option for the treatment of locally advanced/metastatic adenocarcinoma of the pancreas. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1098920 Mon, 17 Dec 2007 15:03:56 +0100 1098920 Neoadjuvant Chemotherapy for Bladder Cancer http://www.medworm.com/index.php?rid=1098919&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204804310%26CID%3Drss Occult distant micrometastasis at the time of radical cystectomy leads predominantly to distant failures in patients with locally advanced muscle-invasive transitional cell carcinoma of the bladder. Cisplatin-based combination chemotherapy enhances survival in patients with metastatic urothelial cancer. Studies evaluating adjuvant chemotherapy have been limited by inadequate statistical power. However, randomized clinical trials have demonstrated a survival benefit for neoadjvuant cisplatin-based combination chemotherapy, which should be considered a standard of care. In addition, neoadjuvant therapy may assist in the rapid development of novel systemic therapy regimens, since pathologic complete remission appears to be a powerful prognostic factor for long-term outcomes. Patients who are ... ConsultantLive news http://www.medworm.com/rss/comments.php?id=1098919 Mon, 17 Dec 2007 15:03:56 +0100 1098919 Neoadjuvant Chemotherapy for Bladder Cancer http://www.medworm.com/index.php?rid=1098918&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204804304%26CID%3Drss Occult distant micrometastasis at the time of radical cystectomy leads predominantly to distant failures in patients with locally advanced muscle-invasive transitional cell carcinoma of the bladder. Cisplatin-based combination chemotherapy enhances survival in patients with metastatic urothelial cancer. Studies evaluating adjuvant chemotherapy have been limited by inadequate statistical power. However, randomized clinical trials have demonstrated a survival benefit for neoadjvuant cisplatin-based combination chemotherapy, which should be considered a standard of care. In addition, neoadjuvant therapy may assist in the rapid development of novel systemic therapy regimens, since pathologic complete remission appears to be a powerful prognostic factor for long-term outcomes. Patients who are ... ConsultantLive news http://www.medworm.com/rss/comments.php?id=1098918 Mon, 17 Dec 2007 15:03:56 +0100 1098918 Neoadjuvant Chemotherapy for Bladder Cancer http://www.medworm.com/index.php?rid=1098917&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204804293%26CID%3Drss Occult distant micrometastasis at the time of radical cystectomy leads predominantly to distant failures in patients with locally advanced muscle-invasive transitional cell carcinoma of the bladder. Cisplatin-based combination chemotherapy enhances survival in patients with metastatic urothelial cancer. Studies evaluating adjuvant chemotherapy have been limited by inadequate statistical power. However, randomized clinical trials have demonstrated a survival benefit for neoadjvuant cisplatin-based combination chemotherapy, which should be considered a standard of care. In addition, neoadjuvant therapy may assist in the rapid development of novel systemic therapy regimens, since pathologic complete remission appears to be a powerful prognostic factor for long-term outcomes. Patients who are ... ConsultantLive news http://www.medworm.com/rss/comments.php?id=1098917 Mon, 17 Dec 2007 15:03:56 +0100 1098917 Highlights in Cancer Care 2007 http://www.medworm.com/index.php?rid=1097807&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204804761%26CID%3Drss 10 notable developments and events in cancer research and care (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1097807 Mon, 17 Dec 2007 01:59:03 +0100 1097807 Clinical Malignant Hematology http://www.medworm.com/index.php?rid=1097806&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204804760%26CID%3Drss The self-stated mission of Clinical Malignant Hematology is to provide a comprehensive and clinically focused guide to the management of patients with hematologic malignancies. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1097806 Mon, 17 Dec 2007 01:59:03 +0100 1097806 City-Dwelling Women at Greater Risk for Breast Cancer http://www.medworm.com/index.php?rid=1097805&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204804754%26CID%3Drss Women who live in urban areas have denser breasts, making them more likely to develop breast cancer, according to a study presented recently at the annual meeting of the Radiological Society of North America (RSNA). (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1097805 Mon, 17 Dec 2007 01:59:03 +0100 1097805 Cetuximab Improves Survival in Advanced Colorectal Cancer http://www.medworm.com/index.php?rid=1097804&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204804753%26CID%3Drss multicenter, open-label, randomized phase III trial recently published in the New England Journal of Medicine (357:2040-2048, 2007) demonstrated that cetuximab (Erbitux) as a single agent significantly improved overall survival in patients with metastatic colorectal cancer (mCRC) refractory to approved chemotherapy agents. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1097804 Mon, 17 Dec 2007 01:59:03 +0100 1097804 Medicare Increases Hospital Reimbursement Rates for Prostate Cancer Cryoablation http://www.medworm.com/index.php?rid=1097803&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204804752%26CID%3Drss federal Centers for Medicare and Medicaid Services (CMS) have increased their hospital outpatient and ambulatory surgical center reimbursement rates for cryoablation treatments for prostate cancer (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1097803 Mon, 17 Dec 2007 01:59:03 +0100 1097803 FDA Clears Test for Monitoring Metastatic Colorectal Cancer http://www.medworm.com/index.php?rid=1097802&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204804746%26CID%3Drss US Food and Drug Administration (FDA) has granted an expanded clearance for the CellSearch System to be used as an aid in the monitoring of metastatic colorectal cancer (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1097802 Mon, 17 Dec 2007 01:59:03 +0100 1097802 Sorafenib First FDA-Approved Drug for Liver Cancer http://www.medworm.com/index.php?rid=1097801&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204804745%26CID%3Drss US Food and Drug Administration (FDA) has approved a supplemental New Drug Application for sorafenib (Nexavar) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC). (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1097801 Mon, 17 Dec 2007 01:59:03 +0100 1097801 Cervical Cancer Candidate Vaccine Provides Sustained Immune Response in Women up to Age 55 http://www.medworm.com/index.php?rid=1097800&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204804744%26CID%3Drss Phase III data showed that at 18 months after the first of a three-dose regimen, 100% of women up to age 55 vaccinated with the GlaxoSmithKline (GSK) cervical cancer candidate vaccine (Cervarix) had antibodies present against the two most common cancer-causing human papillomavirus types, 16 and 18 (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1097800 Mon, 17 Dec 2007 01:59:03 +0100 1097800 What Is the Optimal Initial Treatment for Chronic Lymphocytic Leukemia? http://www.medworm.com/index.php?rid=1097327&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204804242%26CID%3Drss For decades, initial therapy for chronic lymphocytic leukemia (CLL) consisted of alkylators such as chlorambucil (Leukeran). The introduction of nucleoside analogs such as fludarabine and monoclonal antibodies such as rituximab (Rituxan) markedly changed the initial therapy of CLL, particularly in the United States. Fludarabine and combination regimens such as fludarabine/cyclophosphamide (FC) have achieved higher complete response (CR) rates and progression-free survival (PFS) than chlorambucil in previously untreated CLL, but long-term overall survival has not improved, due to concurrent improvement in salvage therapy of relapsed CLL patients. Upfront chemoimmunotherapy regimens such as fludarabine/rituximab (FR) and fludarabine/cyclophosphamide/rituximab (FCR) have similarly improved CR... ConsultantLive news http://www.medworm.com/rss/comments.php?id=1097327 Sun, 16 Dec 2007 02:06:58 +0100 1097327 Clinical Data Suggest Potential Versatility of Pemetrexed-Based Regimens in Lung Cancer http://www.medworm.com/index.php?rid=1097326&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204804233%26CID%3Drss Pemetrexed (Alimta) showed additional utility in the treatment of non–small-cell lung cancer (NSCLC) (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1097326 Sun, 16 Dec 2007 02:06:58 +0100 1097326 What Is the Optimal Initial Treatment for Chronic Lymphocytic Leukemia? http://www.medworm.com/index.php?rid=1097325&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204804287%26CID%3Drss For decades, initial therapy for chronic lymphocytic leukemia (CLL) consisted of alkylators such as chlorambucil (Leukeran). The introduction of nucleoside analogs such as fludarabine and monoclonal antibodies such as rituximab (Rituxan) markedly changed the initial therapy of CLL, particularly in the United States. Fludarabine and combination regimens such as fludarabine/cyclophosphamide (FC) have achieved higher complete response (CR) rates and progression-free survival (PFS) than chlorambucil in previously untreated CLL, but long-term overall survival has not improved, due to concurrent improvement in salvage therapy of relapsed CLL patients. Upfront chemoimmunotherapy regimens such as fludarabine/rituximab (FR) and fludarabine/cyclophosphamide/rituximab (FCR) have similarly improved CR... ConsultantLive news http://www.medworm.com/rss/comments.php?id=1097325 Sun, 16 Dec 2007 02:06:58 +0100 1097325 What Is the Optimal Initial Treatment for Chronic Lymphocytic Leukemia? http://www.medworm.com/index.php?rid=1097324&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204804286%26CID%3Drss For decades, initial therapy for chronic lymphocytic leukemia (CLL) consisted of alkylators such as chlorambucil (Leukeran). The introduction of nucleoside analogs such as fludarabine and monoclonal antibodies such as rituximab (Rituxan) markedly changed the initial therapy of CLL, particularly in the United States. Fludarabine and combination regimens such as fludarabine/cyclophosphamide (FC) have achieved higher complete response (CR) rates and progression-free survival (PFS) than chlorambucil in previously untreated CLL, but long-term overall survival has not improved, due to concurrent improvement in salvage therapy of relapsed CLL patients. Upfront chemoimmunotherapy regimens such as fludarabine/rituximab (FR) and fludarabine/cyclophosphamide/rituximab (FCR) have similarly improved CR... ConsultantLive news http://www.medworm.com/rss/comments.php?id=1097324 Sun, 16 Dec 2007 02:06:58 +0100 1097324 High-Dose Chemo with Stem Cell Transplant Shows Little to No Survival Benefit in Adjuvant Setting http://www.medworm.com/index.php?rid=1096309&cid=s_35770_49_f&fid=35770&url=http%3A%2F%2Fwww.consultantlive.com%2FshowArticle.jhtml%3FarticleID%3D204803582%26CID%3Drss When used as adjuvant therapy for node-positive breast cancer, the combination of high-dose chemotherapy (HDC) and stem cell transplantation modestly improves relapse-free survival relative to standard-dose chemotherapy (SDC). But it offers at best minimal benefit in terms of overall survival, according to a meta-analysis presented at SABCS. (Source: ConsultantLive) ConsultantLive news http://www.medworm.com/rss/comments.php?id=1096309 Sat, 15 Dec 2007 02:19:26 +0100 1096309